Petros Petropoulos signs MoU to buy Ismailos vehicle sales and service business for EUR 21 million
Bitget2026/10/06 14:24Petros Petropoulos signed an MoU to potentially acquire the vehicle sales and after-sales operations of A. Ismailos. Scope includes Ismailos’ 100%-owned subsidiary, an authorized Toyota distributor and repairer in Greece since 2025. The target business has been an authorized Mercedes-Benz distributor and repairer in Attica since 1990. 2025 consolidated revenue from the operations totaled EUR 124,350,000. Deal value estimated at EUR 21 million, subject to due diligence, supplier consents, and potential competition clearance. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Petros Petropoulos SA published the original content used to generate this news brief on October 06, 2026, and is solely responsible for the information contained therein.
- Petros Petropoulos signed an MoU to potentially acquire the vehicle sales and after-sales operations of A. Ismailos.
- Scope includes Ismailos’ 100%-owned subsidiary, an authorized Toyota distributor and repairer in Greece since 2025.
- The target business has been an authorized Mercedes-Benz distributor and repairer in Attica since 1990.
- 2025 consolidated revenue from the operations totaled EUR 124,350,000.
- Deal value estimated at EUR 21 million, subject to due diligence, supplier consents, and potential competition clearance.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley raises CME Group price target to $337
Chip design software leader Synopsys seeks collaboration with Chinese large model laboratories

Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.